WO2004018449A8 - Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4) - Google Patents

Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)

Info

Publication number
WO2004018449A8
WO2004018449A8 PCT/EP2003/008673 EP0308673W WO2004018449A8 WO 2004018449 A8 WO2004018449 A8 WO 2004018449A8 EP 0308673 W EP0308673 W EP 0308673W WO 2004018449 A8 WO2004018449 A8 WO 2004018449A8
Authority
WO
WIPO (PCT)
Prior art keywords
pde4 inhibitors
piperidine
derivatives
meanings
compounds
Prior art date
Application number
PCT/EP2003/008673
Other languages
English (en)
Other versions
WO2004018449A1 (fr
Inventor
Geert Jan Sterk
Steffen Weinbrenner
Armin Hatzelmann
Johannes Barsig
Degenhard Marx
Hans-Peter Kley
Johannes A M Christiaans
Wiro M P B Menge
Original Assignee
Altana Pharma Ag
Geert Jan Sterk
Steffen Weinbrenner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Geert Jan Sterk, Steffen Weinbrenner filed Critical Altana Pharma Ag
Priority to AU2003255376A priority Critical patent/AU2003255376A1/en
Publication of WO2004018449A1 publication Critical patent/WO2004018449A1/fr
Publication of WO2004018449A8 publication Critical patent/WO2004018449A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Ces composés correspondant à la formule (I), formule dans laquelle les substituants sont tels que définis dans le descriptif, sont de nouveaux inhibiteurs efficaces de la PDE4.
PCT/EP2003/008673 2002-08-10 2003-08-06 Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4) WO2004018449A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003255376A AU2003255376A1 (en) 2002-08-10 2003-08-06 Piperidine-derivatives as pde4 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02017979.2 2002-08-10
EP02017979 2002-08-10

Publications (2)

Publication Number Publication Date
WO2004018449A1 WO2004018449A1 (fr) 2004-03-04
WO2004018449A8 true WO2004018449A8 (fr) 2004-05-06

Family

ID=31896829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008673 WO2004018449A1 (fr) 2002-08-10 2003-08-06 Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)

Country Status (2)

Country Link
AU (1) AU2003255376A1 (fr)
WO (1) WO2004018449A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP4778449B2 (ja) 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2625664C (fr) 2005-10-21 2016-01-05 Novartis Ag Molecules organiques
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
US8304436B2 (en) * 2007-05-16 2012-11-06 Nycomed Gmbh Pyrazolone derivatives as PDE4 inhibitors
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
EP2467383A1 (fr) 2009-08-20 2012-06-27 Novartis AG Composés d'oximes hétérocycliques
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (fr) 2011-02-23 2016-08-10 Intellikine, LLC Composés hétérocycliques et leurs utilisations
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN103582644B (zh) 2011-06-17 2016-07-20 塔科达有限责任公司 酞嗪酮-吡咯并嘧啶羧酰胺衍生物
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (fr) 2011-09-15 2018-07-18 Novartis AG 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
WO2013038386A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Composés hétérocycliques destinés au traitement de la mucosviscidose
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
CA3139634A1 (fr) 2019-06-10 2020-12-17 Novartis Ag Derive de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336573A (en) * 1997-01-15 2000-10-27 Byk Gulden Lomberg Chem Fab 4-Phenyl substituted phthalazin-1-one derivatives useful for treating airway disorders
EP1042319B1 (fr) * 1997-12-15 2004-02-04 ALTANA Pharma AG Dihydrobenzofurans
WO1999031071A1 (fr) * 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux phtalazinones
PT1070056E (pt) * 1998-03-14 2004-11-30 Altana Pharma Ag Inibidores de pde iii/iv a base de ftalazinona
AU7654200A (en) * 1999-09-14 2001-04-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
ATE374189T1 (de) * 1999-10-25 2007-10-15 Nycomed Gmbh Phthalazinon-derivate als pde 4 hemmer
CZ20021457A3 (cs) * 1999-10-25 2002-07-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopyranové sloučeniny
SK11382003A3 (sk) * 2001-02-15 2004-01-08 Altana Pharma Ag Piperidino-deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
PL363312A1 (en) * 2001-04-25 2004-11-15 Altana Pharma Ag Novel phthalazinones

Also Published As

Publication number Publication date
WO2004018449A1 (fr) 2004-03-04
AU2003255376A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004018449A8 (fr) Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)
WO2004018457A8 (fr) Piperidine-phthalazones a substitution pyrrolidinedione utilises comme inhibiteurs de la phosphodiesterase-4 (pde4)
WO2004018451A8 (fr) Derives de pyridazinone utilises comme inhibiteurs de pde4
RS20050117A (en) Novel benzonaphthyridines
WO2005087724A3 (fr) Nouvelles hydroxy-6-phenylphenanthridines a substitution amido
WO2003093269A3 (fr) Pyrazolopyrimidine-4-one substituee
WO2006058700A8 (fr) Derives d'acetamides employes en tant que fongicides
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
WO2004018431A3 (fr) Nouvelles phenanthridines
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
WO2004076450A8 (fr) Derives de pyrazolopyridine
AU2003286711A1 (en) Indazolinone compositions useful as kinase inhibitors
WO2005074603A3 (fr) Utilisation d'aminobenzoxazoles comme agents therapeutiques
WO2001017973A3 (fr) Nouveaux herbicides
AU2002349754A1 (en) Novel 1,2,4-triazole compound
WO2005066151A3 (fr) Inhibiteurs d'histone desacetylase
ZA200608416B (en) Herbicidal composition
WO2002085906A3 (fr) Phtalazinones
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
HK1096548A1 (en) Imidazopyridine-derivatives as inductible no-synthase inhibitors
EP1671948A4 (fr) Compose de cinnamoyle et utilisation de ce compose
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
WO2005061496A8 (fr) Derives aminopyridines en tant qu'inhibiteurs de la no-synthase inductible-
EP1671961A4 (fr) Compose cinnamoyle et utilisation associee
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BR CA CN CO DZ EC GE HR ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL SG TN UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 10/2004 REPLACE "(72) INVENTORS " BY "(72) INVENTORS (FOR ALL DESIGNATED STATES EXCEPT CA, PH, US)"

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP